We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Heart Attack Biomarkers Accurate in Chronic Kidney Disease Patients

By LabMedica International staff writers
Posted on 19 Oct 2014
Print article
Two blood peptide biomarkers that are indicators of heart attack in the general population also provide critical information regarding heart status in chronic kidney disease patients.

High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the general population. However, the interpretation of levels of these biomarkers as predictors of HF was uncertain among patients with chronic kidney disease (CKD).

Investigators at the University of Washington (Seattle, USA) and the University of Pennsylvania (Philadelphia, USA) examined whether hsTnT and NT-proBNP were associated with incidents of HF among patients with CKD. In a prospective cohort analysis, they studied 3,483 people with CKD in the Chronic Renal Insufficiency Cohort (CRIC) Study who had been recruited from June of 2003 to August of 2008 and who were free of HF at time zero. The overall health of these individuals was monitored for a median of nearly six years.

Results revealed that compared with those individuals with the lowest levels of hsTnT at the start of the study, those with the highest hsTnT levels had a nearly five-fold higher risk of developing heart failure. Those with the highest NT-proBNP levels had a nearly 10-fold higher risk of developing heart failure compared with those with the lowest levels. Thus, hsTnT and NT-proBNP were shown to be strongly associated with incidents of HF among a diverse cohort of individuals with mild to severe CKD. Elevations in these biomarkers may indicate subclinical changes in volume and myocardial stress that subsequently contributed to clinical HF.

“This research is important in that it may advance the application of widely available cardiac biomarkers to identify CKD patients at the highest risk of developing heart failure, the most common cardiovascular complication in this patient population,” said first author Dr. Nisha Bansal, assistant professor of medicine at the University of Washington.

“These findings suggest that hsTnT and NT-proBNP may represent distinct biological pathways that likely involve subclinical changes in the structure and function of the heart,” said contributing author Dr. Amanda Anderson, assistant professor of biostatistics and epidemiology at the University of Pennsylvania.

The study was published in the October 2, 2014, online edition of the Journal of the American Society of Nephrology.

Related Links:

University of Washington
University of Pennsylvania


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA
New
Centrifuge
Centrifuge 5430/ 5430 R

Print article

Channels

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.